Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 68 Publications

11 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).



    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).



    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.



    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 MonPR5l1d3SxeHnjJGF{e2G7 MXK0PEBp NGTLV3dFVVOR M4C4TGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNE43OiEQvF2= MnXRNlE2PzJ3OEm=
BAF3 MkP0R5l1d3SxeHnjJGF{e2G7 NIr1RlE1QCCq NYjjdYszTE2VTx?= M3myfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugUFEyQT[PIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNk4zKM7:TR?= MoHXNlE2PzJ3OEm=
BAF3 MVjDfZRwfG:6aXOgRZN{[Xl? NWDkPGRFPDhiaB?= Ml6wSG1UVw>? NWXQdlhCS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFXNUFQuSUyNIIfpeIghUUN3MDDv[kAxNjJ6IN88US=> MV[yNVU4OjV6OR?=
Kelly MUDDfZRwfG:6aXOgRZN{[Xl? MYDEUXNQ NXW1cmdDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU2WubImgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC52MjFOwG0> MlzVNlE2PzJ3OEm=
SH-SY5Y Mo\2R5l1d3SxeHnjJGF{e2G7 NUjvVYRbTE2VTx?= M4XZb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC53MzFOwG0> M2rzdFIyPTd{NUi5
BAF3 NXT0R2J7S3m2b4TvfIlkKEG|c3H5 Mmm5OFghcA>? MkPuSG1UVw>? MnvGR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3BUGshf2m2aDDJR|UxKG:oIECuNVkh|ryP M{LZ[lIyPTd{NUi5
3T3 MnnUSpVv[3Srb36gRZN{[Xl? NHfQNIIyKGh? M1nXRWROW09? NIjhWGRKdmirYnn0bY9vKG:oIGLPUkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? NHPPbXgzOThzMkSxOC=>
3T3-E NI\p[W5HfW6ldHnvckBCe3OjeR?= NIP4RlYyKGh? MVHEUXNQ MlnITY5pcWKrdHnvckBw\iCWSVWyJIF{e2W|c3XkJIdzd3e2aDDmZYN1d3JvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjR2ODFOwG0> M1\PNVIyQDF{NEG0
A549 NGTsclFMcW6jc3WgRZN{[Xl? NXLkU5BNOSCq NXuyXVhbTE2VTx?= MXLJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KGNvTVXUJItqdmG|ZTDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDIS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxQCEQvF2= NXPlVpFrOjF6MUK0NVQ>
BAF3-BCL NIf6VnNHfW6ldHnvckBCe3OjeR?= M1;SNVEhcA>? NX3aZ5BKTE2VTx?= NFmxeotKdmirYnn0bY9vKG:oIFHCUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMT6xOVkh|ryP Mn;XNlE5OTJ2MUS=
HEK293 NHPZe3FHfW6ldHnvckBCe3OjeR?= MWixJIg> Mn;qSG1UVw>? NV7NUHRHUW6qaXLpeIlwdiCxZjDBXGwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNlk1KM7:TR?= M3XLd|IyQDF{NEG0
HEK293 MWDGeY5kfGmxbjDBd5NigQ>? MVSxJIg> M1XXZ2ROW09? NXrlfFNPUW6qaXLpeIlwdiCxZjDJVkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj64PFch|ryP MVmyNVgyOjRzNB?=
Jurkat M4rGfGZ2dmO2aX;uJGF{e2G7 MYixJIg> MnzqSG1UVw>? MmDVTY5pcWKrdHnvckBw\iCOQ1ugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwN{SxJO69VQ>? Mn7LNlE5OTJ2MUS=
KARPAS299 MULLbY5ie2ViQYPzZZk> NELWO5UyKGh? M2W4XGROW09? MlP4TY5pcWKrdHnvckBw\iCDTFugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO M4Ly[|IyQDF{NEG0
PAE MlrESpVv[3Srb36gRZN{[Xl? MWOxJIg> NFP1U5NFVVOR M3ruS2lvcGmkaYTpc44hd2ZiVGLLRkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6zPVkh|ryP M2Tm[VIyQDF{NEG0
BAF3 NYP1eWhqTnWwY4Tpc44hSXO|YYm= M4HGblIuOyCm MnrDSG1UVw>? NE\meotKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDpcpN2dGmwIILlZ4VxfG:{IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS54NEOg{txO NYLXeHpxOjN5NEKyOVI>
EBC1 M2r1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXDO|IhcA>? NUfNdlM6TE2VTx?= M134N2lEPTB;MD6wNlMh|ryP NYPyRnV7OjN7OUOzNlg>
HCT116 MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TDT|czKGh? NV;KPGtJTE2VTx?= NYfkRm5OUUN3ME2xOE45OiEQvF2= MWWyN|k6OzN{OB?=
MCF7 M2OzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq3NkBp NWnXWIRmTE2VTx?= NES0NmVKSzVyPUmuOVgh|ryP NIPZUFczOzl7M{OyPC=>
MDA-MB-231 NHrIRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;GPWZbPzJiaB?= MlnnSG1UVw>? MVHJR|UxRTFyLkig{txO NHjSZ3MzOzl7M{OyPC=>
MKN45 M3TrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLhO|IhcA>? M2HMXWROW09? M4H4PGlEPTB;MD6wNVMh|ryP NGH0flgzOzl7M{OyPC=>
NCI-H441 NV;P[I9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzVbFE4OiCq NXHiOZdtTE2VTx?= NF3FdmxKSzVyPUG3MlI2KM7:TR?= MUGyN|k6OzN{OB?=
NCI-H661 NFTvOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTFZ2VVPzJiaB?= MnLRSG1UVw>? MXTJR|UxRTFzLkS3JO69VQ>? MY[yN|k6OzN{OB?=
SKOV3 M4P3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\q[2ZYPzJiaB?= NXfWZpdtTE2VTx?= M4DTZmlEPTB;MUKuPFUh|ryP M1rhOlI{QTl|M{K4
SNU5 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu3NkBp Ml65SG1UVw>? MnLOTWM2OD1yLkCxOkDPxE1? NWXWZ4xCOjN7OUOzNlg>
NCI-H2228 M3m1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVm3NkBp MnTmSG1UVw>? M1zLWmlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFzODFOwG0> Mk\XNlQ1OzJ7MEm=
NCI-H3122 M1LXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWmzR4ZtPzJiaB?= Mn3kSG1UVw>? M4X5VWlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFyODFOwG0> NWX0OIhVOjR2M{K5NFk>
NCI-H3122 NFP1RY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOyO|IhcA>? MlrSSG1UVw>? NY\YW|NjUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshTzF{NknBJI12fGGwdDD3bZRpKEmFNUCgc4YhOC54MkOg{txO NYq0XIpsOjR2M{K5NFk>
NCI-H3122 NWrUWWdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnUb2ZMPzJiaB?= NID6dVVFVVOR M2D3e2lvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIHnuJIh2dWGwIF7DTU1JOzF{MjDj[YxteyCqYYLic5JqdmdiQVzLJGwyOTl4TTDteZRidnRid3n0bEBKSzVyIH;mJFAvQDN6IN88US=> MUKyOFQ{OjlyOR?=
NIH-3T3 NYHkNlRbU2mwYYPlJGF{e2G7 NG\1NZkyKGh? MXvEUXNQ NEjGeWdKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCHTVy0MYZ2e2WmIFHMT{BmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0[YQhSUyNIHzleoVtKHerdHigTWM2OCCxZjCwMlA5KM7:TR?= NV3rdodrOjR2M{K5NFk>
NIH-3T3 M2TwXGtqdmG|ZTDBd5NigQ>? NFzCNWcyKGh? NUGyT3l6TE2VTx?= MmSzTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVI3QUFibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54MEWg{txO NEixO20zPDR|MkmwPS=>
NIH-3T3 M4\JSWtqdmG|ZTDBd5NigQ>? M1\kSFEhcA>? MVjEUXNQ MnzpTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDTNVIxPllibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54Mk[g{txO NUjXd4xsOjR2M{K5NFk>
NIH-3T3 MlzpT4lv[XOnIFHzd4F6 NInsTnQyKGh? M2LvSWROW09? NFXiR3VKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLki0N{DPxE1? NV;5W5BwOjR2M{K5NFk>
NIH-3T3 M3fpbWtqdmG|ZTDBd5NigQ>? NEns[VgyKGh? NGfidHJFVVOR MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVUzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjB{NjFOwG0> M2TWWlI1PDN{OUC5
BAF3 MY\GeY5kfGmxbjDBd5NigQ>? MnXrO|IhcA>? MX;EUXNQ NFjCdW9KdmirYnn0bY9vKG:oIF7QUU9CVEtidILhcpNn\WO2ZXSgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yNUGg{txO MXGyOFQ3QDZ|Mh?=
NIH-3T3 NELOdmJMcW6jc3WgRZN{[Xl? NWjRRmo4OSCq MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjR5ODFOwG0> MV:yOFgyQTFzNh?=
NIH-3T3 NYj4[3gyU2mwYYPlJGF{e2G7 M4qybVEhcA>? NEXWTppKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjB{UjDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iBzLkG0PEDPxE1? M13WOFI1QDF7MUG2
KARPAS299 MXzLbY5ie2ViQYPzZZk> NXH4Zox{QTBibXnu M{DwXGROW09? NEfSRWJKdmirYnn0bY9vKG:oIF7QUU1nfXOnZDDBUGsheGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMD6xNUDPxE1? MUeyOFkxODd3MB?=
MKN 45 M3PPXWtqdmG|ZTDBd5NigQ>? MY[xJIg> NWPEOVRrTE2VTx?= MXTJcohq[mm2aX;uJI9nKGNvTXX0JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> NGTrNlAzPDlyMEe1NC=>
EBC1 NVS2UXJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrmcHlUPzJiaB?= NFrJ[XdFVVOR M2rtR2lEPTBib3[gNE4xODZ7IN88US=> Ml;5NlQ6ODB6M{G=
NB1 NUPnbFdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzXelVRUUN3ME25NU46QCCwTR?= M4i1SHNCVkeHUh?=
NCI-SNU-5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\YUmlEPTB;MUC1Mlc2KG6P NWP4dWl3W0GQR1XS
SF539 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJyND6yOEBvVQ>? M{LtVXNCVkeHUh?=
SU-DHL-1 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGOybIJKSzVyPUOzOk45OiCwTR?= M{LaSXNCVkeHUh?=
CTV-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLuTWM2OD13OU[uOFghdk1? MWjTRW5ITVJ?
EM-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD6VGV2UUN3ME22NFEvOzRibl2= M{j1O3NCVkeHUh?=
KM12 M3rOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[3VnBKSzVyPUewOk46KG6P Ml7XV2FPT0WU
KINGS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP2TWM2OD15NEmuO|Uhdk1? MVPTRW5ITVJ?
MEG-01 M{KyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{mzeGlEPTB;OEW3MlY3KG6P MlzYV2FPT0WU
LAMA-84 MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\COI5KSzVyPUGuN|gzQDJizszN MVrTRW5ITVJ?
KARPAS-299 NYr3Z254T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvDXopKSzVyPUGuOFA5PjFizszN M1;GNHNCVkeHUh?=
K-562 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrPTWM2OD1zLkeyNlY6KM7:TR?= Mm\uV2FPT0WU
SK-LMS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\qZ2lEPTB;MT63Olg3PyEQvF2= MXXTRW5ITVJ?
MOLT-16 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfDTXNrUUN3ME2xMlk2PTd3IN88US=> NEnwPI9USU6JRWK=
CMK MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmwTWM2OD1zLkm2NVU6KM7:TR?= MoTUV2FPT0WU
ST486 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zofGlEPTB;Mj60N|A4OyEQvF2= MWDTRW5ITVJ?
CI-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwNEm2OVkh|ryP M2XBdHNCVkeHUh?=
ALL-PO NHfIU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LVV2lEPTB;Mz6xPFIxPyEQvF2= M1fvdnNCVkeHUh?=
KS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTWOHpiUUN3ME2zMlIyOjJ3IN88US=> Mn31V2FPT0WU
Becker M1HMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGmxfXVKSzVyPUSuNlM6OyEQvF2= MVHTRW5ITVJ?
GDM-1 M4PGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT1bZpMUUN3ME20MlI1PjF5IN88US=> MlfTV2FPT0WU
BC-1 M3S1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTRwNEmyO|ch|ryP NHfpSYlUSU6JRWK=
NB14 M{e0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTRwOEO1NlQh|ryP M{TqN3NCVkeHUh?=
NOS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTVwM{O4O|Qh|ryP M1K2UXNCVkeHUh?=
MZ1-PC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf2epd3UUN3ME21MlgzOTVzIN88US=> NUXlbm1XW0GQR1XS
A498 NGPpPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPRb3JMUUN3ME22MlA5PDd|IN88US=> MmToV2FPT0WU
EW-16 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\vZ2lEPTB;Nj6zO|c4OyEQvF2= MULTRW5ITVJ?
NALM-6 M{HKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3QTWM2OD14Lk[4N|g4KM7:TR?= NGPFOlFUSU6JRWK=
EB-3 NWPwWW1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fvb2lEPTB;Nz6wO|I{OyEQvF2= MVPTRW5ITVJ?
697 NGm4NGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[xcopLUUN3ME25MlI1OzJ7IN88US=> NXPQcXVYW0GQR1XS
Ramos-2G6-4C10 NHLYXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3tTWM2OD17LkW5PFQzKM7:TR?= NIrkV3NUSU6JRWK=
KNS-81-FD M1;IdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW1ZmU5UUN3ME25MlY6PjV|IN88US=> MVLTRW5ITVJ?
HUTU-80 Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnQOI1OUUN3ME25Mlc1PjR{IN88US=> MljoV2FPT0WU
LS-411N MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPs[HVKSzVyPUGwMlA2PjdizszN M2X3eXNCVkeHUh?=
RPMI-8402 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH0bGFKSzVyPUGwMlEyPiEQvF2= NHvtNIxUSU6JRWK=
KU812 M{jvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\aepFEUUN3ME2xNE4zQTlzIN88US=> M3vzPXNCVkeHUh?=
EW-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFyLkS0NlUh|ryP M1vDdHNCVkeHUh?=
HC-1 NGDsVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWxTWM2OD1zMD60PFQ1KM7:TR?= NHr3b3JUSU6JRWK=
NB69 M4i0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\QOpFKSzVyPUGwMlUxPDNizszN NY\T[3M{W0GQR1XS
MFH-ino MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUToPZB2UUN3ME2xNE45OzB|IN88US=> M4fnPHNCVkeHUh?=
SK-N-DZ MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHo[YpKSzVyPUGyMlA1OzZizszN MoDIV2FPT0WU
HCC1187 NX7ZcIh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF{LkKwOFEh|ryP MkfhV2FPT0WU
IST-SL2 NHvQbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF{LkS4O|Ih|ryP NXnxeGltW0GQR1XS
KE-37 M1LKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPzSnNKSzVyPUGyMlc6PjZizszN NWDnZmVCW0GQR1XS
A4-Fuk MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfxZ2pKSzVyPUGyMlk2QDZizszN M2\WPHNCVkeHUh?=
NKM-1 NHHv[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF|LkK5NlUh|ryP MXnTRW5ITVJ?
BE-13 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF|Lke5PFkh|ryP M{nmNHNCVkeHUh?=
MV-4-11 M3G5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XoPGlEPTB;MUSuNFMzPCEQvF2= MVjTRW5ITVJ?
OPM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnYU2JKSzVyPUG0MlQxQDVizszN M4\VOHNCVkeHUh?=
KARPAS-422 M{i1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLvWFNKSzVyPUG0MlUyOjZizszN NYGx[VVxW0GQR1XS
RPMI-8226 NXH0NWRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLrfWNKSzVyPUG0Mlg6OTVizszN M{\2XHNCVkeHUh?=
LC-2 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF4LkG1NFYh|ryP M2SycXNCVkeHUh?=
NCI-H1648 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfydFlKSzVyPUG2MlI2PCEQvF2= NYXkRlVXW0GQR1XS
RL95-2 NEPEcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:weZc3UUN3ME2xOk4{QTd6IN88US=> MV7TRW5ITVJ?
KNS-42 NFnQb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrueWd6UUN3ME2xOk44Ojd2IN88US=> MkLWV2FPT0WU
RPMI-6666 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm1TWM2OD1zNj65NlEyKM7:TR?= MkfxV2FPT0WU
SIG-M5 M3rscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PTSmlEPTB;MUeuNVkxOyEQvF2= M3i2N3NCVkeHUh?=
VA-ES-BJ NH3SNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPrcm9KSzVyPUG3Mlc1PTFizszN NYj3em96W0GQR1XS
LAN-6 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3oelhKSzVyPUG4Mlc2PTdizszN MoOxV2FPT0WU
A388 NEjZe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILHXWJKSzVyPUG5MlMxPTlizszN NYjjUlFbW0GQR1XS
TE-10 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPpTWM2OD1{MD61NlIyKM7:TR?= MWHTRW5ITVJ?
HL-60 M4jOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPoTGJKSzVyPUKwMlkxQTlizszN NVHW[YI{W0GQR1XS
MC116 NXTuPYRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr1TWM2OD1{MT63NlIyKM7:TR?= NW\GbGZxW0GQR1XS
SW962 NFf4cWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[0bWlEPTB;MkGuO|kyPSEQvF2= MX3TRW5ITVJ?
NOMO-1 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJ{Lk[1OlQh|ryP NUjC[mU1W0GQR1XS
CTB-1 MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm0U|dKSzVyPUKyMlg3PzFizszN NXnFSlB2W0GQR1XS
MRK-nu-1 M3TnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH5bZF3UUN3ME2yNk46ODd2IN88US=> M123WXNCVkeHUh?=
GR-ST M4j4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v5fWlEPTB;MkOuO|Yh|ryP NGrOTXJUSU6JRWK=
HH MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJ2LkCwN{DPxE1? Mm\XV2FPT0WU
NCI-H1963 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPyTWM2OD1{ND6wO|gzKM7:TR?= MkC5V2FPT0WU
QIMR-WIL NHjWZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljkTWM2OD1{ND64O|czKM7:TR?= MnTaV2FPT0WU
CGTH-W-1 NF3RPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\XTWM2OD1{NT6wO|I{KM7:TR?= NV6xR3hWW0GQR1XS
PF-382 Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnjTWM2OD1{Nz6yNlI{KM7:TR?= M4jBVnNCVkeHUh?=
ATN-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ5LkO3N|Ih|ryP M2DOfnNCVkeHUh?=
L-540 M17PTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTvTWM2OD1{Nz62OFU6KM7:TR?= M4LBfnNCVkeHUh?=
LXF-289 NFvITJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnITWM2OD1{Nz63OVE6KM7:TR?= M4XKTnNCVkeHUh?=
LS-513 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ6LkG4NFch|ryP M1i0enNCVkeHUh?=
NCI-H1581 NH3helBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTNyLkO5O|Yh|ryP MmrEV2FPT0WU
ES6 NUHZcXJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jiUmlEPTB;M{CuOlg6QSEQvF2= M2\4[XNCVkeHUh?=
SW982 NFXDcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXMRYpKSzVyPUOwMlg2PjZizszN M{LIV3NCVkeHUh?=
DOHH-2 NH3ld2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHUV|RKSzVyPUOxMlU5QTNizszN MmDqV2FPT0WU
DB M2O0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnhelhWUUN3ME2zN{46PDNzIN88US=> MlK3V2FPT0WU
MPP-89 NHyzWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfUTWM2OD1|ND6xO|U3KM7:TR?= NX;LN3FuW0GQR1XS
NB5 M2nsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfNOohKSzVyPUO0Mlg2OzVizszN MkTFV2FPT0WU
TE-15 NEH0dnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i5O2lEPTB;M{WuNlI{QCEQvF2= MnjTV2FPT0WU
NCI-H747 NF34UGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWixZo81UUN3ME2zOk4yOzZ7IN88US=> MYTTRW5ITVJ?
NTERA-S-cl-D1 NIq2eVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXpeFBKSzVyPUO4Mlc{PDdizszN M4r1eXNCVkeHUh?=
SK-MM-2 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe4TWM2OD12MD6xNVQ3KM7:TR?= NWnwOIxbW0GQR1XS
ONS-76 MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTR{LkS4PFMh|ryP NXrkOmQ4W0GQR1XS
CPC-N NF7OU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTR{Lkm5O|Eh|ryP M1Hx[XNCVkeHUh?=
ES4 NIqzcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP2TWM2OD12ND60NVU{KM7:TR?= MXfTRW5ITVJ?
Daudi MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jRPWlEPTB;NEWuNFgzPyEQvF2= MX;TRW5ITVJ?
MOLT-4 NFvmZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjnfXNxUUN3ME20OU4xQDV|IN88US=> M4jicXNCVkeHUh?=
HT-144 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR4LkeyOkDPxE1? MW\TRW5ITVJ?
D-283MED MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TMUGlEPTB;NEiuN|U1OiEQvF2= NVnVTm9JW0GQR1XS
NCI-H2126 MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHDS5hKSzVyPUS4Mlg1PzZizszN NIrFe2NUSU6JRWK=
CESS M{[5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrRNoRlUUN3ME20PU42ODh6IN88US=> MoiwV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]


Kinase Assay:[1]
+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:[1]
+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method: Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO+30% PEG 300+dd H2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34


CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID